Biologics initiation in moderate versus severe rheumatoid arthritis: real-world experience from a Canadian registry
Authors' conclusion
Severe RA patients had higher mean score improvements in DAS28, sleep and fatigue. Moderate RA was more likely to reach remission or LDA. Both groups had similar biologic persistence at 12 months.
Study context
- Population
- Biologic-naive rheumatoid arthritis (RA) patients initiating their first biologic in the Ontario Best Practices Research Initiative registry, 2008–2020initiated first biologic
- Participants
- 838 patients
- Exposure
- Moderate vs severe RA at first biologic initiation
- Moderate RAn = 264
- Severe RAn = 219reference
- Outcome
- Remission
- Follow-up
- 12 months
Methodological detailsreal-world, Ontario Best Practices Research Initiative registry, 2008–2020
- Real-world
- Ontario Best Practices Research Initiative registry, 2008–2020
Main finding
As reported in the abstract
P < 0.0001
Observational data: associations, not effects.
Further findings
LDA · 12 months
P < 0.0001
Mean
| Outcome | Moderate RA | Severe RA | P value |
|---|---|---|---|
| Change from baseline in DAS28 · 12 months | 1.4 (SD 1.3) | 2.2 (SD 1.5) | P < 0.0001 |
| Change from baseline in fatigue score · 12 months | 0.98 (SD 3.2) | 1.11 (SD 3.2) | P < 0.0001 |
Characteristics associated with remission · 12 months
- Moderate disease at biologic initiation positively associated with remission
- P = 0.0016
- Female gender negatively associated with remission
- P = 0.0170
- Higher baseline HAQ-DI negatively associated with remission
- P = 0.0042
Biologic persistence · 12 months
- Biologic persistence, moderate
- 77%
- Biologic persistence, severe
- 73%
- Moderate vs severe
- P = 0.2444
Original publication
Biologics initiation in moderate versus severe rheumatoid arthritis: real-world experience from a Canadian registry. Clin Exp Rheumatol. Published 14 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →